Comparing the current results to its competitors, Casi Pharmaceuticals Inc reported Revenue decrease in the 4 quarter 2025 year on year by -27.42 %, despite the revenue increase by the most of its competitors of 10.62 %, recorded in the same quarter.
Casi Pharmaceuticals inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 13.2 %
Casi Pharmaceuticals Inc 's Comment on Competition and Industry Peers
EVOMELA® faces significant competition from generic melphalan products in China, which have reduced its market share. In 2025, one new generic injectable melphalan product entered the market, with three additional generic applications under review by the Center for Drug Evaluation (CDE). These generics, generally priced lower, have increased pricing and marketing pressures, attracting cost-conscious healthcare providers and institutions away from branded products like EVOMELA®. Government-owned hospitals in China restrict drug use to their hospital formularies, making formulary inclusion essential for drug adoption and reimbursement. The company must participate in provincial-level tendering processes to achieve formulary listing; however, winning a tender does not guarantee hospital inclusion. Additionally, EVOMELA® may be included in the National Reimbursement Drug List (NRDL) under China's insurance policy, which automatically covers any drug sharing the same generic name once a competitor's drug is added.
2seventy Bio Inc operates on a business model centered around the development and commercialization of innovative genetic therapies. They strive to harness the power of biotechnology to address complex diseases and improve patient outcomes. By advancing their proprietary gene delivery technologies and collaborating with industry partners, they aim to create scalable treatments that revolutionize the field of genetic medicine.
Pulmatrix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative inhaled therapies for respiratory diseases. Their business model revolves around creating novel inhaled drug delivery technologies and collaborating with partners to advance their product pipeline, aiming to provide effective treatments for patients with respiratory conditions.
Ligand Pharmaceuticals Inc operates on a business model focused on discovering and acquiring new drugs and technologies to license them to pharmaceutical companies. They generate revenue through licensing fees, milestone payments, and royalties from the sales of their partnered products. Their approach allows them to leverage their expertise and resources while minimizing risk, ultimately leading to long-term value creation for their shareholders.
Sources:
Casi Pharmaceuticals inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Casi Pharmaceuticals inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
